New cell therapy tested for patients with rare, Treatment-Resistant blood disorder
NCT ID NCT07091370
Summary
This is an early-stage study to test the safety and find the right dose of a new cell therapy called Inaticabtagene Autoleucel for people with autoimmune hemolytic anemia (AIHA). The study will enroll up to 12 adults in China whose AIHA has not improved after trying at least three other standard treatments. The main goal is to see how well patients tolerate the treatment and to check for side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AIHA - COLD AUTOIMMUNE HEMOLYTIC ANEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.